glp-1 half life Recent updates on agonists: Current advancements & challenges A) Half-life extension mechanisms of

10.1056/NEJMoa1916038 N Engl J Med

Brian Robinson, Global Chief Strategy Officer, Havas is at the forefront of the Havas GLP-1 consultancy, guiding clients through the immediate risks and opportunities of these groundbreaking drugs

The FDA has received reports of dosing errors associated with compounded GLP-1s, including patients accidentally taking too much or too little and experiencing complications such as fainting, dehydration and severe gastrointestinal symptoms

Some people naturally land at 1,2001,500 calories daily, while others maintain 1,8002,000 calories and still lose weight steadily

This leads to common "mystery symptoms" that many of our clients at Blue Horizon describe: persistent fatigue, feeling cold, brain fog, and weight gain that seems resistant to change

The analysis identified two main symptom categories that may warrant further investigation